厄达替尼中国有吗？

Erdafitinib is a once-daily oral pan-fibroblast growth factor receptor that blocks fibroblast growth factor receptor activity and is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have genetic mutations or fusions in the genes for FGFR2 or FGFR3. In the phase II study, 32% of patients treated with erdafitinib experienced complete or complete tumor shrinkage, with 2% experiencing complete regression. The average response time is 5.4 months. It was first approved in 2019. Erdafitinib represents the first personalized treatment for patients with metastatic bladder cancer who have predisposing FGFR gene alterations.

Erdafitinib is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who:

(1) FGFR3 or FGFR2 gene mutation;

(2) Disease progression during or after at least one previous platinum-based chemotherapy regimen, including within 12 months of treatment with neoadjuvant or adjuvant platinum-based chemotherapy regimens.

Is erdafitinib available in China?

Erdafitinib is already on the market in Hong Kong. Patients in need can go to Hong Kong to purchase erdafitinib. According to Medical Companion Travel, the specification of erdafitinib imported into Hong Kong is 4mg*28 tablets and the price is about $106,500. Please consult Medical Companion Travel for the specific price! 

If it is inconvenient for you to go to Hong Kong to purchase, the most reliable way is to purchase it through a formal overseas medical service institution in China, which will sign a protection contract for you. The medicine and money will not be handled by you, and will be mailed to the patient by direct mail, guaranteeing 100% authenticity!

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: